Network Version
Estramustine phosphate sodium Data Sheet
| Product Name: | Estramustine phosphate sodium |
 |
|---|---|---|
| CAS No.: | 52205-73-9 | |
| Cat. No.: | HY-13627 | |
| MWt: | 564.35 | |
| Formula: | C23H30Cl2NNa2O6P | |
| Purity : | >98% | |
| Solubility: | DMSO : 5 mg/mL (ultrasonic);H<sub>2</sub>O : 62.5 mg/mL (ultrasonic) | |
| Mechanisms: | Target: Cancer Endocrinology Inflammation/Immunology | |
| Biological Activity: | ||
| Estramustine phosphate sodium, an estradiol analog, is an orally active antimicrotubule chemotherapy agent. Estramustine phosphate sodium depolymerises microtubules by binding to microtubule associated proteins (MAPs) and/or to tubulin. Estramustine phosphate sodium can interfere mitosis, trigger cell death and induce apoptosis, which can be used for the research of cancer like prostate cancer[1][2][3]. In Vitro: Estramustine phosphate sodium (1 µg/ mL, 48 h) suppresses PC3 cell growth[1]. Estramustine phosphate sodium (2 µg/mL, 48 h) elevates phosphatidylserine eversion amount on PC3 cells and induces PC3 cell apoptosis through reducing miR-31[1]. Estramustine phosphate sodium (0-40 µM, 24-72 h) inhibits cell proliferation and tubulin cytoskeleton in RAW 264.7 cells[2]. Estramustine phosphate sodium (10 µM, 24 h) inhibits TGF-β-induced RAW 264.7 cell migration, as well as TGF-β-induced uPA production by inhibiting Smad3 activation[2]. In Vivo: Estramustine phosphate sodium (Intraperitoneal injection, 4 or 12 mg/kg, a daily dose for 2 weeks) inhibits PAC120 tumor growth 53% by day 35[3]. | ||
1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA
Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] Web:www.medchemexpress.com